SHARDACROP780.20

Sharda Cropchem Ltd.

· Chemicals
₹ CrorePeersUPLPIINDSTYRENIXREFEXSUDARSCHEMSUDEEPPHRMRCFRALLISMcap ₹7,039 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SHARDACROP
FY26
UPL
FY26
PIIND
FY26
STYRENIX
FY26
Peer
Median
Valuation — at last close
P/E10.34×25.72×27.03×20.53×25.72× -60%
P/B2.24×1.18×3.18×2.75×2.75× -18%
EV/EBITDA6.00×6.90×20.24×11.38×11.38× -47%
Market Cap₹7,039 Cr₹48,507 Cr₹35,766 Cr₹3,755 Cr₹35,766 Cr -80%
Growth
Revenue CAGR 3Y9.20%-1.09%1.13%13.17%1.13% +714%
Revenue CAGR 5Y17.07%6.02%7.96%16.08%7.96% +114%
Net Income CAGR 3Y25.81%-20.47%2.42%-0.03%-0.03% +86133%
Revenue YoY (latest Q)9.03%10.47%-10.43%7.14%7.14% +26%
Net Income YoY (latest Q)-38.36%58.52%-38.95%166.37%58.52% -166%
Profitability
EBITDA Margin20.43%17.89%25.32%9.98%17.89% +14%
Net Income Margin12.93%4.28%19.67%5.32%5.32% +143%
Return on Common Equity21.70%4.66%11.58%13.38%11.58% +87%
Return on Capital Employed22.15%9.97%11.08%12.05%11.08% +100%
Return on Assets11.78%2.33%9.82%7.37%7.37% +60%
Credit & Quality
Total Debt/Equity0.00×0.53×0.02×0.23×0.23× -100%
Interest Coverage427.86×1.77×78.84×11.78×11.78× +3532%
Scale — latest FY
Revenue / Total Income₹5,268 Cr₹51,839 Cr₹6,714 Cr₹3,438 Cr₹6,714 Cr -22%
Net Income₹681 Cr₹2,220 Cr₹1,321 Cr₹183 Cr₹1,321 Cr -48%
Total Assets₹5,780 Cr₹95,205 Cr₹13,444 Cr₹2,483 Cr₹13,444 Cr -57%
EPS₹75.47₹22.32₹87.06₹103.98₹87.06 -13%
Book Value per Share₹347.71₹488.39₹738.85₹776.75₹738.85 -53%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.